−4117.54USD
−11.90 MUSD
421.26 K
About Allarity Therapeutics, Inc.
Sector
CEO
Thomas H. Jensen
Headquarters
Boston
Website
Employees (FY)
6
Founded
2021
ISIN
US0167444019
FIGI
BBG012NXCZP8
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
$ALLR Is It A Noteworthy Drug Stock?The five-year mortality rate for women with metastasized breast cancer is 30%. However, that statistic figure may soon be curbed due to Allarity Therapeutics, Inc.’s (NASDAQ: ALLR) new treatment – IXEMPRA-DRP. This is a treatment system combining Ixempra, an FDA-approved treatment for Metastasized b
Allarity priming itself for a pumpAs with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten.
Then, in a move to regain compliance (if i
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ALLR is 1.42 USD — it has decreased by 7.79% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Allarity Therapeutics, Inc. stocks are traded under the ticker ALLR.
Allarity Therapeutics, Inc. is going to release the next earnings report on May 24, 2024. Keep track of upcoming events with our Earnings Calendar.
ALLR stock is 14.49% volatile and has beta coefficient of 3.42. Check out the list of the most volatile stocks — is Allarity Therapeutics, Inc. there?
ALLR earnings for the last quarter are −44.80 USD per share, whereas the estimation was −163.44 USD resulting in a 72.59% surprise. The estimated earnings for the next quarter are −5.00 USD per share. See more details about Allarity Therapeutics, Inc. earnings.
Yes, you can track Allarity Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ALLR stock has fallen by 50.87% compared to the previous week, the month change is a 78.45% fall, over the last year Allarity Therapeutics, Inc. has showed a 99.73% decrease.
ALLR net income for the last quarter is −1.72 M USD, while the quarter before that showed −4.45 M USD of net income which accounts for 61.28% change. Track more Allarity Therapeutics, Inc. financial stats to get the full picture.
Today Allarity Therapeutics, Inc. has the market capitalization of 725.61 K, it has decreased by 11.67% over the last week.
No, ALLR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALLR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Allarity Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 6.00 employees. See our rating of the largest employees — is Allarity Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Allarity Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Allarity Therapeutics, Inc. stock shows the sell signal. See more of Allarity Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.